TMTino Münster

Tino Münster

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tino Münster has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Determination of the Long‐Term Stability of Propofol in Human Plasma Frozen for Eight Years and Quantified by UHPLC–MS/MS

    by Stefanie Schmidt, Harald Ihmsen, Tino Münster, Jürgen Schüttler, Christian Jeleazcov, Andreas Wehrfritz

    The intravenous anesthetic propofol is frequently used for the induction and maintenance of general anesthesia. Propofol has, however, a potential for abuse, and it has been involved in suicide deaths particularly among medical personnel. The long‐term stability of propofol concentrations in human plasma samples when stored under normal laboratory conditions over several years might be important for forensic toxicology. The present study investigated the long‐term stability of propofol after storage at −20°C for eight years. For this purpose, 67 plasma samples from five patients, who had undergone a former clinical trial, were re‐analyzed. Plasma samples were extracted using protein precipitation. Propofol plasma concentrations were determined by ultra‐performance liquid chromatography (UPLC) with gradient elution, followed by tandem mass spectrometry with electrospray ionization. Deuterium‐labeled propofol was used as an internal standard. The assay was linear in the range of 50–10,000 ng/mL with a limit of detection of 0.5 ng/mL and a lower limit of quantification of 50 ng/mL, respectively. Accuracy and precision were high with intra‐ and interassay errors within ±5%. The median relative deviation between the measurements in 2023 and 2015 was −7.0% (interquartile range: −19.7% and 5.3%). Therefore, propofol concentrations in human plasma can be considered relatively stable in samples frozen at −20°C over eight years, and plasma samples stored under these conditions might be used for forensic purposes. Trial Registration: ClinicalTrials.gov identifier: NCT02199067

  • Open Access

    Correction to: Transient receptor potential ankyrin 1 promoter methylation and peripheral pain sensitivity in Crohn’s disease

    by Sara Gombert, Mathias Rhein, Andreas Winterpacht, Tino Münster, Thomas Hillemacher, Andreas Leffler, Helge Frieling

    An amendment to this paper has been published and can be accessed via the original article.


  • Open Access

    Intravenous theophylline is the most effective intervention to prolong EEG seizure duration in patients undergoing electroconvulsive therapy

    by Alexander Tzabazis, Michaela E. Wiernik, Jan Wielopolski, Wolfgang Sperling, Harald Ihmsen, Hubert J. Schmitt, Tino Münster

    Seizure duration in electroconvulsive therapy (ECT) is positively related with patients’ outcome. This study sought to investigate the impact of anesthetic management on seizure duration, and the impact of selected drugs (theophylline, remifentanil, S-ketamine) on seizure duration. Retrospective analysis of all patients undergoing ECT at our institution from January 2011 to April 2012 was performed based on electronic medical chart and review of existing quality improvement data. Patient data (N = 78), including gender, age, height, weight, and administered drugs, energy levels, and electroencephalic seizure duration were analyzed. Statistical analysis was performed using a generalized linear model. A total of 78 patients (male = 39, female = 39, age 51 ± 12 years) were included. Average number of session was 10 ± 6 (1–30). In our patient population, theophylline administration was the only parameter, which significantly prolonged seizure duration, whereas S-ketamine, remifentanil, thiopental, age, sex, session or energy level had no significant effect. Theophylline can be a useful adjunct for patients with inadequate seizure duration. If there is a concomitant beneficial effect on patients’ outcome needs to be investigated in further studies.